Phase 1-2a Study of EBNA1 Inhibitor, VK-2019, in Patients With Epstein-Barr Virus-positive Nasopharyngeal Cancer

Conditions:   Nasopharyngeal Carcinoma;   Nasopharyngeal Cancer
Intervention:   Drug: VK-2019
Sponsors:   Troy Messick;   Stanford University;   National Cancer Institute (NCI)
Not yet recruiting

https://ift.tt/2xM299D